论文部分内容阅读
一.氯苯吩嗪(Clofazimine) FDA已批准了抗麻风病药物氯苯吩嗪(Lamprene,Ciba—Geigy)。并指定作为治疗结节麻风病的稀有病药物,并早被收入WHO的基本药物名单中。该药与氨苯砜或利福平未见交叉耐药性。因此对氨苯砜有耐药性的病人及对患红斑结节麻风病的患者
I. Clofazimine FDA has approved the anti-leprosy drug, Lamprene (Ciba-Geigy). And designated as a treatment for nodules leprosy of rare diseases, and has long been included in the WHO list of essential medicines. The drug and dapsone or rifampicin no cross-resistance. Therefore, patients with resistance to dapsone and patients with erythema nodules leprosy